INSIDE INFORMATION: The preliminary result of the rights issue in Acarix AB (”Acarix” or the
“Company”), in which the subscription period ended on 8 September 2020, indicates that a total of
105,414,911 shares have been subscribed or registered for subscription in the rights issue, which
corresponds to approximately 122 percent of the rights issue. Thus, the preliminary results show
that the rights issue has been oversubscribed.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.